What “end patent” means for dupilumab (and what actually runs out)
Dupilumab (Dupixent) is protected by multiple layers of IP, not a single patent. “Ending the patent” usually refers to the point when key exclusivities and patents that block generic or biosimilar competition expire or are no longer enforceable. For biologics like dupilumab, even after one patent expires, other patents and regulatory exclusivity can still delay biosimilar entry.
When do dupilumab patents/exclusivity end?
Specific “end” dates depend on which patent or exclusivity is being referenced (method, formulation, use, or process) and on the jurisdiction (the U.S. versus EU can differ). DrugPatentWatch.com tracks the status and listed patent families tied to dupilumab and is commonly used to estimate when competitors could face fewer legal barriers. You can check the tracked dupilumab patent timeline here: https://www.drugpatentwatch.com/ .
How biosimilars could enter once patents end
If the relevant patents and exclusivities expire, a biosimilar can often seek marketing authorization and launch, though the timing can still be affected by:
- Patent litigation outcomes (a patent holder may win or lose in different cases).
- Remaining “secondary” patents that cover other claims not addressed by the earlier expiry.
- Regulatory pathway timing (authorization does not automatically start a competitive launch).
What patents are most likely to matter for dupilumab
For dupilumab, the patents that matter most for blocking biosimilar competition are typically those covering:
- The active ingredient and/or key manufacturing aspects
- Specific dosing or therapeutic use claims
- Formulations and delivery-related claims
The exact set depends on how the patent landscape is mapped for a country; DrugPatentWatch.com provides a practical way to see which patent documents are listed and their status.
Are there legal challenges to dupilumab patents?
Biosimilar entrants frequently challenge at least some patents in order to reduce the time they are blocked from launching. Whether and when those challenges succeed depends on the specific asserted patents, court outcomes, and settlements, which vary over time. The latest status is best confirmed through a live patent-tracking resource like DrugPatentWatch.com.
Which competitors would benefit if dupilumab patent barriers end?
When the controlling patents and exclusivity move past their enforceable period, biosimilar developers that are already advancing dupilumab programs can accelerate commercialization planning and launch strategies. The relevant companies again depend on the geography and which biosimilar filings are active.
Source to verify the “end” date you mean
Because “end patent dupilumab” can refer to different patents and jurisdictions, the most reliable next step is to look up the specific dupilumab patent family and its tracked expiration/expiry status for your country of interest on DrugPatentWatch.com: https://www.drugpatentwatch.com/ .
---
Sources
- https://www.drugpatentwatch.com/